The coronavirus vaccine SARS-CoV-2 (causing the COVID-19) developed by the American Novavax It has shown a positive immune response, despite generating moderate side effects in most participants, the company said in a statement.
The experimental vaccine data are still part of phase 1 and 2 of clinical tests, so they are very preliminary, in addition to having been published but not yet reviewed by the scientific community.
The tests were made at 130 healthy volunteers and everyone who received the vaccine and not the placebo developed antibodies against the SARS-CoV-2.
The most positive response was in those who received two doses three weeks apart, as they developed a four-fold higher antibody level than patients who have recovered from the disease.
80% of the volunteers, recruited in Australia, who received the vaccine developed side effects, especially doloreswhile a 60% had headaches and muscle aches. About eight came to suffer “severe” effects, but from which they recovered in a few days and did not require hospitalization.
The results are promising, but like other pharmaceutical and biotech companies that have joined the race to find the vaccine COVID-19, are not yet conclusive.
Modern, AstraZeneca-Oxford and Pfizer They are already working on recruiting 30,000 volunteers each to begin phase 3 and final clinical trials that determine the vaccine’s efficacy and safety and allow regulators to authorize its mass production.
Novavax, a small pharmacist in Maryland, received $ 1.6 billion to work on the development of the vaccine by the US government’s Operation Warp Speed.
“Phase 1 data shows that NVX-CoV2373 is a vaccine from COVID-19 Well tolerated with a robust immunogenetic profile, “Novavax President Gregory Glenn said in a statement.
Novavax assured that It is preparing to prepare the critical phase 3 of the vaccine tests and to have the capacity to produce 100 million doses once its distribution among the population has been authorized.
EFE
–
